#2-92E. The Epinephrine Paradox: Rethinking Prescription Thresholds in Anaphylaxis (J Allergy Clin Immunol Pract, 2025)

Do our current prescribing habits for epinephrine autoinjectors actually align with objective clinical risk, or are we driven by inconsistent paradigms? This episode examines a provocative Rostrum article highlighting a glaring disparity: clinicians frequently prescribe autoinjectors for food allergies carrying a low anaphylaxis risk (under 5%) while often withholding them for venom allergies with significantly higher recurrence risks (over 30-50%). The authors argue that this inconsistency is not supported by evidence regarding hospitalization or mortality reduction. The most critical clinical insight offered is that prescribing to low-risk individuals may paradoxically harm quality of life by fueling anxiety and reinforcing a perception of danger, rather than offering reassurance. However, when critically appraising this claim, physicians must note the significant evidence gap; the authors highlight that only two studies have specifically assessed the impact of device provision on quality of life, limiting the robustness of this conclusion. For clinicians, this analysis advocates shifting from reflex prescribing toward nuanced, shared decision-making that weighs medical necessity against the potential psychological burdens of lifelong autoinjector carriage.

Citation: Turner PJ, Patel N, Adams K, et al. Inconsistences in Prescribing Epinephrine Autoinjectors. J Allergy Clin Immunol Pract. 2025. DOI: 10.1016/j.jaip.2025.07.045

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.